Clinical Trial Record

Return to Clinical Trials

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer


2025-02-01


2026-02-01


2026-02-01


30

Study Overview

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.

Pancreatic cancer is one of the solid cancers with the poorest treatment outcomes, and there is an urgent need to improve its treatment outcomes. Among these, resectable pancreatic cancer is known to show relatively good treatment outcomes with surgical resection, but the 5-year survival rate is still about 20%, which is still unsatisfactory. Neoadjuvant therapy may increase the proportion of patients that actually receive chemotherapy and thereby improve survival. Furthermore, neoadjuvant therapy may increase the microscopically margin-negative (R0) resection rate and may identify patients with rapidly progressive disease who can be spared futile surgery.

  • Surgery
  • Neoadjuvant Chemotherapy
  • Management
  • Resectable Pancreatic Cancer
  • PROCEDURE: Immediate surgery
  • PROCEDURE: Neoadjuvant chemotherapy
  • 1437/02/2025

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2025-05-10  

N/A  

2025-05-10  

2025-05-10  

N/A  

2025-05-18  

2025-05-18  

N/A  

2025-05  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
: Immediate surgery group

Patients will undergo upfront surgery, then adjuvant chemotherapy.

PROCEDURE: Immediate surgery

  • Patients will undergo upfront surgery, then adjuvant chemotherapy.
: Neoadjuvant chemotherapy group

Patients will undergo neoadjuvant chemotherapy, then surgery.

PROCEDURE: Neoadjuvant chemotherapy

  • Patients will undergo neoadjuvant chemotherapy, then surgery.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Overall survival rateOverall survival will be measured as the time between date of randomization and date of death from any cause or date of last follow-up if alive.1 year post-procedure
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Achieve of R0 ResectionResection is defined as the number of patients with an R0 resection margin. R0 resection margin rate will be measured according to the Africa Regional Collaborative Platform (RCP) report on standards and datasets for reporting cancers.1 year post-procedure
Disease free survivalDisease-free survival will be measured as the time between date of surgery and date of disease recurrence.1 year post-procedure
Time to locoregional recurrenceTime to locoregional recurrence will be recorded.1 year post-procedure
Time to distant metastasisTime to distant metastasis will be recorded.1 year post-procedure
Incidence of postoperative complicationsIncidence of postoperative complications such as hemorrhage and pancreatic fistula will be recorded.1 year post-procedure

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Abdelrahman M Salah, MD

Phone Number: 00201064746493

Email: Abdelrahman.salah@mu.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Computed tomography (CT) with pancreatic protocol + vascular mapping
  • Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis & Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein & portal vein.

  • Exclusion Criteria:

  • Borderline resectable & locally advanced pancreatic cancer
  • Tumor at the tail of the pancreas.
  • Metastatic pancreatic cancer
  • Unfit patients for surgery.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available